Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This study is aimed to comprehensively establish the bio-similarity/bioequivalence in EPIAO®
and EPREX® in terms of 52-week comparisons in efficacy, safety and immunogenicity. The
targeted population is anaemia patients with end-stage chronic renal disease who previously
received epoetin treatment and on haemodialysis.